Table 3.
Distribution of Focal/Grid Laser Treatments Received
| Sham + Prompt Laser | Ranibizumab + Prompt Laser | Ranibizumab + Deferred Laser∥ | Triamcinolone + Prompt Laser | |
|---|---|---|---|---|
| Number of laser treatments received prior to the 1 year visit, no. (%)* | N = 274 | N = 171 | N = 178 | N = 176 |
| 0 | 1 (<1%)† | 0 | 124 (70%) | 1 (1%)‡ |
| 1 | 35 (13%) | 53 (31%) | 36 (20%) | 46 (26%) |
| 2 | 75 (27%) | 54 (32%) | 17 (10%) | 53 (30%) |
| 3 | 107 (39%) | 46 (27%) | 1 (1%) | 49 (28%) |
| 4 | 56 (20%) | 18 (11%) | 0 | 27 (15%) |
| Proportion of eyes receiving laser at 48 week visit, no. (%)* | 242 (26%) | 155 (16%) | 160 (8%) | 154 (21%) |
| Number of laser treatments received prior to the 2 year visit, no. (%)§ | N = 163 | N = 106 | N = 112 | N = 103 |
| 0 | 1 (1%) | 0 | 65 (58%) | 0 |
| 1 | 14 (9%) | 21 (20%) | 21 (19%) | 16 (16%) |
| 2 | 28 (17%) | 24 (23%) | 7 (6%) | 23 (22%) |
| 3 | 38 (23%) | 23 (22%) | 11 (10%) | 28 (27%) |
| 4 | 29 (18%) | 22 (21%) | 8 (7%) | 13 (13%) |
| 5 | 25 (15%) | 9 (8%) | 0 | 11 (11%) |
| 6 | 13 (8%) | 5 (5%) | 0 | 7 (7%) |
| 7 | 15 (9%) | 2 (2%) | 0 | 5 (5%) |
*
Includes study participants completing the 1-year (52 week) visit.
†
One eye did not receive laser until post 1-year due to an adverse event unrelated to study treatment.
‡
One eye did not receive laser until after 1-year due to missing 2 consecutive visits at the initial time of required laser treatment.
§
Includes study participants completing the 2-year visit.
∥
Three eyes deviated from the protocol and received laser prior to 24 weeks (2 were given laser at the 1 week safety visit and 1 at the 20 week visit).